Vigilant Biosciences, Inc.

www.vigilantbiosciences.com

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer

Read more

Reach decision makers at Vigilant Biosciences, Inc.

Lusha Magic

Free credit every month!

Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection of oral cancer. Vigilant’s BeVigilant™ product line includes a point-of-care RAPID test that is simple, accurate and cost-effective, empowering healthcare practitioners to improve lives through earlier intervention. The BeVigilant RAPID Test, the first and only technology that measures the tumor-initiating and stem cell associated biomarkers – markers clinically validated to be associated with oral cancer – to aid clinicians in the early detection of oral cancer. The point-of-care BeVigilant RAPID Test uses a simple collection method that is easy to administer and non-invasive for the patient. The test has the potential to benefit adults at risk of oral cancer, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). The BeVigilant RAPID Test is CE Marked and available in select markets outside of the United States. Leadership: Bill Brodie, Chief Executive Officer Robert T. Hamilton, CPA, Chief Financial Officer Dragan Nebrigic, Ph.D., Chief Operating Officer Ben Beckham, Chief Commercial Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer

Read more
icon

Country

icon

State

Florida

icon

City (Headquarters)

Fort Lauderdale

icon

Employees

11-50

icon

Founded

2011

icon

Estimated Revenue

$1,000,000 to $5,000,000

icon

Social

  • icon
  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chief Commercial Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Financial Officer

    Email ****** @****.com
    Phone (***) ****-****
  • Board Member

    Email ****** @****.com
    Phone (***) ****-****
  • Chief Executive Officer

    Email ****** @****.com
    Phone (***) ****-****

Technologies

(21)

Reach decision makers at Vigilant Biosciences, Inc.

Free credits every month!

My account

Sign up now to uncover all the contact details